NASDAQ$KALV
KalVista Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
KalVista reported financial results for the fourth quarter and fiscal year ended April 30, 2022.
KalVista Pharmaceuticals reported no revenue for the three months ended April 30, 2022. Research and development expenses were $19.2 million, and general and administrative expenses were $7.6 million. The net loss for the quarter was $24.1 million, or $(0.98) per share. Cash, cash equivalents, and marketable securities totaled $166.2 million as of April 30, 2022.
- Enrollment is proceeding as expected for the Phase 3 KONFIDENT trial for sebetralstat, with data expected in the second half of 2023.
- The Phase 2 KOMPLETE clinical trial for KVD824 also remains on track with its enrollment targets, and data from the KOMPLETE trial is expected in mid-2023.
- KalVista reported promising preclinical data for its oral factor XIIa inhibitor program at the KININ2022 conference.
- The Company is well-capitalized, with funding until at least early 2024, which is expected to take them beyond data from both ongoing clinical trials.
Headline financials
Revenue & EPS history
KalVista · Revenue · Quarterly
$13.7M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.3%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.7%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+20.3%
Q4 2018
Best reaction
-26.3%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +1.1% | +26.3% | +56.4% | |
| Q1 2026 | -3.8% | -12.3% | -25.3% | |
| Q4 2025 | -3.1% | -5.1% | -22.4% | |
| Q3 2025 | +2.0% | -2.6% | +5.1% | |
| Q2 2025 | -4.2% | -0.2% | -4.5% | |
| Q1 2025 | -4.5% | -13.2% | -12.1% | |
| Q4 2024 | +3.7% | +21.3% | +2.6% | |
| Q3 2024 | -13.0% | -16.9% | -16.9% | |
| Q2 2024 | -9.0% | +8.8% | +26.8% | |
| Q1 2024 | -4.0% | -4.2% | -12.2% | |
| Q4 2023 | +17.0% | +7.6% | +23.5% | |
| Q3 2023 | -10.4% | -1.3% | +2.7% | |
| Q2 2023 | +9.8% | +7.3% | +27.8% | |
| Q1 2023 | +1.4% | -2.5% | -68.4% | |
| Q4 2022 | +10.6% | +18.0% | +37.5% | |
| Q3 2022 | -9.3% | -14.6% | -16.4% | |
| Q2 2022 | -0.4% | -2.9% | -4.2% | |
| Q1 2022 | -0.6% | -6.0% | -14.4% | |
| Q4 2021 | -3.0% | -2.9% | -14.0% | |
| Q3 2021 | +3.4% | +8.9% | -16.8% | |
| Q2 2021 | +5.2% | +5.1% | -7.0% | |
| Q1 2021 | +2.0% | +1.3% | +9.8% | |
| Q4 2020 | +7.2% | +4.2% | -18.8% | |
| Q3 2020 | -26.3% | -41.2% | -20.9% | |
| Q2 2020 | -1.8% | -5.7% | +18.9% | |
| Q1 2020 | +8.7% | +1.0% | -29.4% | |
| Q4 2019 | -0.5% | +1.4% | -6.7% | |
| Q3 2019 | +10.4% | +7.6% | -0.2% | |
| Q2 2019 | -14.0% | -21.2% | -15.5% | |
| Q1 2019 | +9.6% | +4.6% | +20.6% | |
| Q4 2018 | +20.3% | +29.8% | +94.0% | |
| Q3 2018 | +4.7% | +11.7% | +0.8% | |
| Q2 2018 | -4.8% | -12.3% | +0.2% | |
| Q1 2018 | -21.5% | -23.6% | +9.8% | |
| Q4 2017 | -0.8% | -2.7% | -11.6% | |
| Q3 2017 | +1.9% | -1.0% | -12.2% | |
| Q2 2017 | -1.9% | -2.9% | -1.6% | |
| Q1 2017 | +0.4% | +13.1% | -13.3% | |
| Q4 2016 | -3.2% | — | — | |
| Q3 2016 | +7.1% | — | — | |
| Q2 2016 | -3.2% | — | — | |
| Q1 2016 | +1.3% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro